FDA Approves Groundbreaking Gene Therapy Restoring Hearing in Deaf Children

In a lab room, a toddler, deaf from birth, sits while a tone plays. There’s no reaction. His face does not change. Six weeks later, after a single injection of an experimental gene therapy, the same toddler is back in the same room. The tone plays. The toddler’s head turns toward the sound. And somewhere just off screen, the child’s grandfather says his name. The boy turns and looks. He can hear.

“When the parents realized their child had a response to sound they cried. The whole family cried.”

This moment, captured in a video from Dr. Yilai Shu of the Eye ENT Hospital of Fudan University—who co-led the trial—illustrates the transformative power of gene therapy in 2026. The footage also shows another child, thirteen weeks post-treatment, dancing to music.

These scenes are from the international clinical trial of an OTOF gene therapy conducted by Mass Eye and Ear and China’s Fudan University, which provided the scientific foundation for a new drug approved last week by the U.S. Food and Drug Administration (FDA).

FDA Approves Otarmeni for OTOF-Related Hearing Loss

On April 23, 2026, the FDA granted accelerated approval to Otarmeni, a gene therapy developed by Regeneron for severe-to-profound hearing loss caused by mutations in the OTOF gene.

In a pivotal clinical trial, 80% of treated patients gained measurable hearing, and 42% reached the level needed to pick up whispers. Two and a half years after treatment, 90% of patients in the multi-center trial were still hearing.

From Tragedy to Triumph: The Evolution of Gene Therapy

The approval of Otarmeni represents a historic milestone in gene therapy—a field that nearly collapsed in 1999 after the death of Jesse Gelsinger, a teenager who died four days after receiving an experimental gene therapy at the University of Pennsylvania. His death was the first publicly identified fatality in a gene therapy clinical trial.

The tragedy led to a temporary halt in U.S. gene therapy trials, stricter oversight by the National Institutes of Health (NIH), and a sharp decline in funding and public trust. Careers were derailed, and the term “gene therapy” became synonymous with cautionary tales of unmet expectations.

It took years of rigorous research, regulatory reforms, and technological advancements to rebuild the field. Now, 27 years after Gelsinger’s death, gene therapy has delivered a life-changing treatment for children born with certain types of congenital hearing loss.

The Future of Gene Therapy: Accessibility and Scale

While Otarmeni’s success is a cause for celebration, the next decade will focus on broader challenges: scaling production, ensuring affordability, and expanding access to treatments that currently benefit only a few hundred children annually.

If these hurdles are overcome, what feels like a medical miracle today could become standard care tomorrow. For families like those in the trial, the difference between silence and sound is nothing short of extraordinary.